Bleakley Financial Group LLC raised its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 49.9% in the 4th quarter, according to the company in its most recent filing with the Securities & ...

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.

Bernstein initiated coverage of Biogen (BIIB) with a Market Perform rating and $160 price target For the past five years, Biogen “has lived ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Alzheimer’s Research UK has a large number of different grant schemes through which you can apply for funding. All applications must fall within Alzheimer’s Research UK’s remit which covers biomedical ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...